Skip to main content
MGNX logo

MGNX · Macrogenics Inc

Track MGNX — free
$1.94 -0.11 (-5.37%)
Market Cap
$131.01M
Shares
63.91M
Volume · Nov 18 106.3K Avg daily vol (3M) 709.77K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.05 Open$2.13 Day$2.02–2.18 52W close$1.33–4.86 Avg vol 30d920K Short int4.9M · 7.7% of shares · 3.9d Short vol58% Last earningsMay 20, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

Up next

call held Aug 6, 2024

Latest documents

2026
Nov 13
Current report 8-K
MGC026 shows 27% response rate; cash runway through 2028

MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028.

Regulation FD disclosure
5 source passages
On November 13, 2026, MacroGenics, Inc. (the “Company”) made available an updated version of the Company’s corporate presentation on its website, which reflects updated clinical program details. MGC026 Summary: Promising Development Path in SCCHN 27% Best Overall Response in late line SCCHN 64% Disease control rate $288M Cash equiv. & marketable securities as of September 30, 2026 • Cash runway guidance through 2028 Open the document at this passage
Nov 12
Current report 8-K
Cash reaches $287.7 million as pipeline advances

MacroGenics held $287.7 million in cash, cash equivalents and marketable securities, with cash runway guidance through 2028. It reported a third-quarter net loss of $20.1 million, completed MGC028 dose escalation and dosed the first patient in MGC030’s Phase 1 study.

Financial results
4 source passages
Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028 Net loss was $20.1 million for the quarter ended September 30, 2026, compared to net income of $16.8 million for the quarter ended September 30, 2025. MGC028 is a first-in-class ADC targeting ADAM9, a protein that is overexpressed in multiple solid tumors. Phase 1 dose escalation of this molecule has been completed, and the Company has selected a lead indication. MGC030 is a first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors. Following clearance of the Investigational New Drug (IND) application, the first patient was dosed in a Phase 1 study in patients with advanced solid tumors, including urothelial, colorectal, gastric or gastroesophageal junction, esophageal and pancreatic cancers. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CDMO sale generates $87.5 million pretax gain

Macrogenics sold its CDMO Operations to Bora for a $122.5 million purchase price and received $119.6 million after adjustments, recognizing an $87.5 million pretax gain. Cash runway is expected through 2028, dependent on future partner payments and cost savings.

Revenue $18.67M ▼ 64.8% Net loss $20.08M Diluted EPS -$0.32
Read from the MD&A section
4 source passages
Effective June 30, 2026, we completed the sale of certain assets and liabilities related to our GMP manufacturing operations, including our CDMO business (the CDMO Operations) conducted at our manufacturing facility and related warehouse operations located in Frederick, Maryland to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC (collectively, Bora). Under the terms of the Bora Agreement, Bora paid us $119.6 million in July 2026, which represented the purchase price of $122.5 million net of customary adjustments, including for working capital and indebtedness, and Bora assumed responsibility for the CDMO Operations. During the nine months ended September 30, 2026, we recognized a pretax net gain on sale of $87.5 million within discontinued operations, in connection with the sale. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September 30, 2026, combined with projected and anticipated future payments from our partners, and anticipated savings from our ongoing cost-reduction initiatives, supports our cash runway through 2028. Open the document at this passage
Nov 3
Current report 8-K Events of Oct 30
Independent directors appointed as board expands

MacroGenics appointed Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors effective October 30, 2026, expanding its board from ten to eleven members.

Director or officer change, or executive pay, Regulation FD disclosure
2 source passages
On October 30, 2026, the Board of Directors (the “Board”) of MacroGenics, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee (the “Committee”) of the Board, approved an increase in the size of the Board from ten to eleven members. MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Open the document at this passage
Oct 23
Current report 8-K
Other events

MacroGenics reported interim Phase 1 MGC026 data showing a 27% best overall response rate in heavily pretreated SCCHN patients, with no treatment-related discontinuations, and plans an early 2027 front-line pembrolizumab combination cohort.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$148.71M
Trailing 12 months
Net income (TTM)
−$51.49M
Trailing 12 months
Revenue growth YoY
-64.8%
Year over year
Operating margin
-43.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-31.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$49.03M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
+35.8%
Trailing year
Short interest
7.7%
Latest settlement · 3.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross Death cross
Price vs 200-day avg −41%
below
Price vs 50-day avg −37%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −41%
trailing
6-month return −51%
trailing
YTD return +27%
this year
Relative strength −48%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.74% of shares out · ▼ -2.2% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
131 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Poor
Revenue growth −0%
Y/Y
EPS growth −10%
Y/Y
Free cash flow $-83.0M
Quant / Vol
risk profile
Very High
Volatility 91%
annualized · 1-yr
Max drawdown −58%
past year
ATR 11.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 13, 2026
Aggregate future milestone payments · up to $2.4B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−41% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) Death cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.74% of shares out · ▼ -2.2% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
131 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 20% Range high $5
vs 200-day avg -41% vs 50-day avg -37% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash consideration from Bora $119.6M During the third quarter —
option license payment from Gilead $10M During the third quarter —
regulatory milestone payment from Sanofi $24.5M During the third quarter —
Income from operations of the CDMO Operations $3M the three months ended June 30, 2026 filing —
Net gain on sale of the CDMO Operations $86.1M the three months ended June 30, 2026 filing —
Pretax net gain on sale of CDMO Operations $86.1M the three months ended June 30, 2026 filing —
Pro forma cash, cash equivalents and marketable securities $327M Q2 2026 —
Shares of common stock outstanding 63,645,711 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MGNX
Macrogenics Inc
this stock
$131.01M +27.3% -0.3% — 7.7%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
131
% held
76.6%
Net QoQ
+262.4K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
135
View
Short & Settlement
Short Interest Falling
Shares short
4.9M
Days to cover
3.9d
Change
-110.7K sh
View
Short Volume
Short vol %
58%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
172
Value
$640
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
35.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$149.5M
Net income (FY)
$-74.6M
EPS diluted
$-1.18
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
24

MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028.

View
Proposed Sales
Value
$798.8K
Shares
51.4K
Filed
Apr 4, 2024
View
Earnings & Events
Webcasts
Last webcast
May 20, 2026
View
Investor Relations
Latest news
MacroGenics Announces Appointment…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
MGNX -15.3% -41.3% -51.3% -14.6% +27.3%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -13.0% -36.5% -48.4% -11.5% +19.9%
Key facts CIK 1125345 CUSIP 556099109 13F (30d) 143 filings 127 filers Visit website Investor relations